Close menu


Sunderland Repository records the research produced by the University of Sunderland including practice-based research and theses.

Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended‐Release Tablets

Al Bawab, Abdel Qader, Alkhalidi, Bashar A., Albarahmieh, Esra'a, Qassim, Sami M.A., Al‐Saifi, Mohammad A.D., Al‐Saifi, Bashar, Ling, Jonathan and Al-Qerem, Waleed (2020) Pharmacokinetics and Bioequivalence Estimation of Two Formulations of Alfuzosin Extended‐Release Tablets. Clinical Pharmacology in Drug Development. ISSN 2160-763X

Item Type: Article


Alfuzosin is a medication approved by the US Food and Drug Administration to treat benign prostatic hyperplasia symptoms. Bioequivalence studies are demanded by regulatory authorities to evaluate the expected in vivo biological similarity of 2 formulations of a medication. The aim of this study is to assess the bioavailability of the generic (test) and branded (reference) formulations of 10‐mg alfuzosin extended‐release tablets after oral administration to healthy adults under fed conditions. The study used a comparative randomized, single‐dose, 2‐way crossover open‐label study design. Thirty‐three participants were recruited and completed the clinical assessment. The pharmacokinetic parameters maximum plasma concentration (Cmax), area under the plasma concentration–time curve (AUC0‐t), AUC extrapolated to infinity (AUC0‐∞), time to maximum concentration, and elimination half‐life were estimated to prove bioequivalence. The confidence intervals for the log‐transformed test/reference ratios for alfuzosin 110.7% (98.0–124.9) and 112.0% (101.9–123.1) for Cmax and AUC0‐t respectively, which are within the allowed limits specified by the regulatory authorities (80–125% for Cmax and AUC0‐t). The test formulation can therefore be prescribed as an alternative to the reference for symptomatic treatment of benign prostatic hyperplasia.

[img] Microsoft Word
203631_1_Alfazusinpaper_final_IJCP_CORRECTED.docx - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (41kB)

More Information

Depositing User: Jonathan Ling


Item ID: 12256
Identification Number:
ISSN: 2160-763X
Official URL:

Users with ORCIDS

ORCID for Jonathan Ling: ORCID iD

Catalogue record

Date Deposited: 17 Jul 2020 08:29
Last Modified: 16 Jul 2021 02:38


Author: Jonathan Ling ORCID iD
Author: Abdel Qader Al Bawab
Author: Bashar A. Alkhalidi
Author: Esra'a Albarahmieh
Author: Sami M.A. Qassim
Author: Mohammad A.D. Al‐Saifi
Author: Bashar Al‐Saifi
Author: Waleed Al-Qerem

University Divisions

Faculty of Health Sciences and Wellbeing


Sciences > Pharmacy and Pharmacology

Actions (login required)

View Item View Item